SCHEMBL10242939

SCHEMBL10242939

CCCCNC(=O)c1cccc(-c2ccco2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.65
ALDH1A1 P00352 5/20 0.63
L3MBTL1 Q9Y468 4/20 0.63
KDM4E B2RXH2 3/20 0.63
POLB P06746 3/20 0.63
HPGD P15428 3/20 0.63
MAPT P10636 3/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
MCL1 Q07820 2/20 0.63
CTDSP1 Q9GZU7 2/20 0.63
ALOX15 P16050 1/20 0.63
CASP1 P29466 1/20 0.63
BLM P54132 1/20 0.63
CASP7 P55210 1/20 0.63
HSD17B10 Q99714 1/20 0.63
KEAP1 Q14145 1/20 0.56
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
CASP6 P55212 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243027 0.96 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242946 0.95 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242978 0.92 KEAP1 (0.58) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242941 0.87 KEAP1 (0.61) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242974 0.85 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10243085 0.84 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL1925893 0.81 SMN1; SMN2 (0.77) SMN1; SMN2L3MBTL1ALOX15NAAAHTT
SCHEMBL12250927 0.81 KEAP1 (0.57) ALDH1A1L3MBTL1KDM4EPOLBHPGD
SCHEMBL16117373 0.80 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1L3MBTL1POLBHPGD
SCHEMBL10243023 0.80 PTPN7 (0.64) ALDH1A1L3MBTL1KDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885ALDH1A1 1939/4885L3MBTL1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.